Wedbush Maintains Outperform on Cullinan Therapeutics, Raises Price Target to $42

Benzinga Newsdesk www.benzinga.com Positive 91.5%

Neg 0% Neu 0% Pos 91.5%

Wedbush analyst Robert Driscoll maintains Cullinan Therapeutics (NASDAQ:CGEM) with a Outperform and raises the price target from $39 to $42.